Medexus Pharmaceuticals Inc. (TSE:MDP) just released its first-quarter report and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.2% to hit US$27m. Medexus Pharmaceuticals reported statutory earnings per share (EPS) US$0.08, which was a notable 15% above what the analysts had forecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Check out our latest analysis for Medexus Pharmaceuticals

After the latest results, the consensus from Medexus Pharmaceuticals' five analysts is for revenues of US$104.3m in 2025, which would reflect a noticeable 4.1% decline in revenue compared to the last year of performance. Per-share earnings are expected to leap 488% to US$0.26. In the lead-up to this report, the analysts had been modelling revenues of US$106.2m and earnings per share (EPS) of US$0.21 in 2025. Although the revenue estimates have not really changed, we can see there's been a sizeable expansion in earnings per share expectations, suggesting that the analysts have become more bullish after the latest result.

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 5.8% to CA$3.05. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Medexus Pharmaceuticals, with the most bullish analyst valuing it at CA$4.40 and the most bearish at CA$2.35 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 5.5% annualised decline to the end of 2025. That is a notable change from historical growth of 19% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 11% per year. It's pretty clear that Medexus Pharmaceuticals' revenues are expected to perform substantially worse than the wider industry.